Sparks commentary - Immix Biopharma

Healthcare

Sparks - Immix Biopharma

More on this equity
Scientist using protective robber gloves for handling substances and experiments
Immix (NASDAQ: IMMX) to present NEXICART-2 update at ASH 2025
Published by Arron Aatkar, PhD

Immix Biopharma has announced that it will present updated clinical data relating to its lead CAR-T asset, NXC-201, in relapsed/refractory amyloid light chain amyloidosis (r/r ALA) at the upcoming American Society of Hematology 2025 Annual Meeting (ASH 2025; 6–9 December). The data will come from the ongoing US-based NEXICART-2 trial, which is a multi-site, Phase I/II clinical study with a registrational design. The most recent clinical update corresponded to 10 out of the expected 40 patients, and hence, the update at ASH 2025 represents an important upcoming catalyst.

Latest

Investment Companies | Comment

The Biotech Growth Trust (BIOG) reported encouraging H126 results

TMT | Comment

Nanoco (LSE:NANO) settles LG litigation for $5m

Healthcare | Comment

Mendus (OMX: IMMU) announces c SEK50m directed share issue